Browse Title Index


 
Issue Title
 
Vol 6, No 3 (2005) Prevenzione e terapia precoce del diabete mellito di tipo II: aspetti farmacoeconomici Abstract   PDF
Lorenzo Pradelli
 
Vol 13, No 2 (2012) Pricing and reimbursement of innovative pharmaceuticals in France and the new healthcare reform Abstract   HTML   PDF
Alexander Natz, Marie-Geneviève Campion
 
Vol 16, No 2 (2015) Process reengineering: the experience of electrophisiology center of the Local Health Unit of Viterbo Abstract   HTML   PDF
Mario Malavasi, Silvia Dari
 
Vol 4, No 4 (2003) Profilo clinico ed economico di oxatomide Abstract   PDF
Lorenzo Pradelli, Mario Eandi
 
Vol 6, No 3 (2005) Profilo farmacologico clinico e farmacoeconomico di un gel oftalmico a base di carbomero 974P e PVA (Siccafluid®) nella terapia della cheratocongiuntivite secca Abstract   PDF
Lorenzo Pradelli, Letizia Vacchini
 
Vol 5, No 2 (2004) Profilo terapeutico e farmacoeconomico di linezolid Abstract   PDF
Mario Eandi
 
Vol 12, No 3 (2011) Prophylaxis against febrile neutropenia with pegfilgrastim in Italy: a budget impact analysis Abstract   HTML   PDF
Giovanni Rosti, Maria Lebboroni, Ario Cerchiari, Pablo Katz
 
Vol 9, No 1 (2008) PROVE-IT trial: economic analysis Abstract   PDF
Simona de Portu, Sabato Montella, Simona Cammarota, Anna Citarella, Lorenzo G. Mantovani
 
Vol 13, No 2S (2012) Puglia Abstract   HTML   PDF
Roberto Gasparini, Donatella Panatto, Bruna Dirodi, Rosa Prato, Gianni Amunni, Valter Turello, Luigi Sudano, Paolo Cristoforoni, Sara Boccalini, Paolo Bonanni
 
Vol 9, No 1S (2008) Puglia Abstract   PDF
Maria Caterina Cavallo, Filippo Cipriani, Simone Gerzeli, Nadia Demarteau, Alessia Marocco, Francesco Bamfi
 
Vol 7, No 3 (2006) Rational and irrational factors in the dynamics of pharmaceutical expenditure and in the drug price negotiation Details   PDF
Mario Eandi
 
Vol 6, No 2 (2005) Razionalizzare la spesa ospedaliera: Day-Hospital, ADI, Hospice Abstract   PDF
Mario Eandi
 
Vol 15, No 2 (2014) Real‑life cost and cost‑effectiveness for tiotropium 18 μg od monotherapy in moderate and severe COPD patients: a 48‑month survey Abstract   HTML   PDF
Massimiliano Povero, Lorenzo Pradelli, Paola Turco, Roberto Walter Dal Negro
 
Vol 18, No 1 (2017) Recently approved recombinant factor VIII (rFVIII) for the replacement treatment in patients with hemophilia A in Italy Details   HTML   PDF
Daniela Paola Roggeri, Ezio Zanon, Alessandro Roggeri
 
Vol 11, No 1 (2010) Regional control of pharmaceutical expenditure in the DL May 31, 2010 No 78 Details   PDF
Mario Eandi
 
Vol 13, No 2S (2012) Regione “Test” Abstract   HTML   PDF
Roberto Gasparini, Donatella Panatto, Bruna Dirodi, Rosa Prato, Gianni Amunni, Valter Turello, Luigi Sudano, Paolo Cristoforoni, Sara Boccalini, Paolo Bonanni
 
Vol 12, No 3 (2011) Report OsMed related to the first nine months of 2011 Details   HTML   PDF
Ombretta Bandi
 
Vol 15, No 2 (2014) Research gaps and Health Technology Assessment Details   HTML   PDF
Leela Barham
 
Vol 7, No 2 (2006) Resistenza all’uso degli ipoglicemizzanti orali nel trattamento del diabete tipo 2: uno studio multicentrico Abstract   PDF
Gianluca Falcitelli, Giuseppe Armentano, Corrado Pugliesi, Patrizio Tatti, Antonio Cimino
 
Vol 14, No 2 (2013) Results of reference pricing and reimbursement discount rate schemes of Turkey Abstract   HTML   PDF
Guvenc Kockaya, Kagan Atikeler, Esin Tuna, Pelin Kılıc, Pelin Tanyeri, Nurcan Umman, İsmail Mert Vural, Omer Altun, Akif Akbulat, Guven Artiran, Ercan Simsek, Hakkı Gursoz, Saim Kerman
 
Vol 5, No 1 (2004) Rettifica al lavoro: considerazione cliniche ed economiche nel trattamento del cancro della prostata: analisi costo/efficacia di bicalutamide vs. flutamide in combinazione con LHRH Details   PDF
Sebastiano Maurizio Castorina
 
Vol 11, No 1 (2010) Revisiting the role of a service-Day Hospital in infectious diseases, based on the natural history of HIV infection in the era of potent antiretroviral combination therapy Abstract   PDF
Roberto Manfredi
 
Vol 6, No 1 (2005) Rifaximina nel trattamento della malattia diverticolare: potenziale terapeutico ed economico Abstract   PDF
Orietta Zaniolo, Mario Eandi
 
Vol 14, No 1 (2013) Role of pharmacoeconomics in developing countries Details   HTML   PDF
Amani Mori, Paul Gavaza, Bjarne Robberstad
 
Vol 9, No 2 (2008) Rotigotine patches (Neupro) in early Parkinson’s disease Abstract   PDF
Viola Sacchi
 
Vol 13, No 2S (2012) Sardegna Abstract   HTML   PDF
Roberto Gasparini, Donatella Panatto, Bruna Dirodi, Rosa Prato, Gianni Amunni, Valter Turello, Luigi Sudano, Paolo Cristoforoni, Sara Boccalini, Paolo Bonanni
 
Vol 9, No 1S (2008) Sardegna Abstract   PDF
Maria Caterina Cavallo, Filippo Cipriani, Simone Gerzeli, Nadia Demarteau, Alessia Marocco, Francesco Bamfi
 
Vol 9, No 2 (2008) Sartans: differences, similitudes and costs Abstract   PDF
Orietta Zaniolo, Sergio Iannazzo
 
Vol 13, No 2S (2012) Sicilia Abstract   HTML   PDF
Roberto Gasparini, Donatella Panatto, Bruna Dirodi, Rosa Prato, Gianni Amunni, Valter Turello, Luigi Sudano, Paolo Cristoforoni, Sara Boccalini, Paolo Bonanni
 
Vol 9, No 1S (2008) Sicilia Abstract   PDF
Maria Caterina Cavallo, Filippo Cipriani, Simone Gerzeli, Nadia Demarteau, Alessia Marocco, Francesco Bamfi
 
Vol 17, No 1S (2016) Simulating the development and progression of Chronic Kidney Disease and osteoporosis in people living with HIV Abstract   HTML   PDF
Silvano Adami, Paolo Maggi, Vincenzo Montinaro, Massimiliano Povero, Lorenzo Pradelli, Rita Bellagamba, Paolo Bonfanti, Antonio Di Biagio, Stefano Rusconi, Francesco Maria Di Campli, Giuseppe Forastieri, Michele Mancini
 
Vol 8, No 1 (2007) Simvastatin: between clinics and health economics Abstract   PDF
Francesco Vittorio Costa, Orietta Zaniolo
 
Vol 9, No 1 (2008) Solifenacin in overactive bladder syndrome: pharmacoeconomic analysis Abstract   PDF
Sergio Iannazzo, Lorenzo Pradelli
 
Vol 1, No 2 (2000) Stato di salute degli italiani e prospettive di spesa sanitaria e farmaceutica Abstract   PDF
Mario Eandi
 
Vol 3, No 4 (2002) Storia naturale dell’infiammazione allergica Abstract   PDF
Maria Angela Tosca, Giorgio Ciprandi
 
Vol 10, No 3 (2009) Sugammadex in antagonism of neuromuscular block in anesthesia: a clinical and economic profile Abstract   PDF
Viola Sacchi, Sergio Iannazzo, Francesco Giunta
 
Vol 6, No 2 (2005) Sulodexide: implicazioni cliniche ed economiche Abstract   PDF
Orietta Zaniolo, Mario Eandi
 
Vol 4, No 3 (2003) Sviluppo e implementazione di un modello farmacoeconomico per valutare la costo efficacia di un ACE-inibitore nella prevenzione del rischio cardiovascolare Abstract   PDF
Sergio Iannazzo, Lorenzo Pradelli, Mario Eandi
 
Vol 7, No 1 (2006) Taxane therapy in the adjuvant treatment of breast cancer in Italy: economic evaluation Abstract   PDF
Simona Ravera, Lorenzo G. Mantovani
 
Vol 9, No 4 (2008) Telbivudine (Sebivo) in patients with hepatitis B virus (HBV) chronic infection Abstract   PDF
Viola Sacchi
 
Vol 7, No 2 (2006) Telithromycin (Ketek®)in lower respiratory tract infections: economic aspects Abstract   PDF
Carlo Lazzaro
 
Vol 6, No 1 (2005) Terapia del dolore: nuove norme e aspetti pratici per l’uso degli analgesici Abstract   PDF
Lorenzo Pradelli
 
Vol 6, No 1 (2005) Terlipressina: profilo farmacologico clinico, terapeutico e farmacoeconomico nel trattamento delle varici esofagee Abstract   PDF
Lorenzo Pradelli
 
Vol 16, No 4 (2015) The aging of Europe. The unexplored potential Details   HTML   PDF
Mihajlo Jakovljevic
 
Vol 7, No 2 (2006) The breakthrough of public pharmaceutical expenditure in 2005 Details   PDF   PDF
Mario Eandi
 
Vol 7, No 3 (2006) The clinical and economic value of lovastatin in the primary prevention of cardiovascular disease Abstract   PDF
Lorenzo Pradelli, Orietta Zaniolo
 
Vol 10, No 2 (2009) The clinical and economic value of the dipeptide alanyl-glutamine in total parenteral nutrition of critically ill patients treated in intensive care units in Italy Abstract   PDF
Maurizio Muscaritoli, Lorenzo Pradelli, Orietta Zaniolo, Sergio Iannazzo, Mario Eandi
 
Vol 18, No 1 (2017) The cost of a combination Anti-Retroviral Therapy (cART) optimization pathway as maintenance therapy in HIV-1 infected patients Abstract   HTML   PDF
Roberto Ravasio, Fabio Rigo, Emanuela Lattuada, Ercole Concia, Massimiliano Lanzafame
 
Vol 13, No 1 (2012) The cost-effectiveness of prevention: is an ounce of prevention worth a pound of cure? Details   HTML   PDF
Steven Simoens
 
Vol 9, No 1 (2008) The discovery of “sale amarissimo antifebbrile” (“bitter febrifugal saline”) by Bartolommeo Rigatelli, i.e. the origins of pharmacoeconomics Abstract   PDF
Piero Marson, Giampiero Pasero
 
Vol 15, No 1S (2014) The economic impact associated with cerebrovascular events related to non-valvular atrial fibrillation (NVAF) in Italy: the role of apixaban Details   HTML   PDF
Lorenzo Pradelli, Mario Calandriello, Roberto Di Virgilio, Marco Bellone, Marco Tubaro
 
Vol 13, No 2 (2012) The effect of obesity upon Health Related Quality of Life (HRQoL): A comparison of the AQoL-8D and SF-36 instruments Abstract   HTML   PDF
Munir Ahmed Khan, Jeff Richardson, Paul O'Brien
 
Vol 12, No 1 (2011) The health and social costs of chronic kidney disease in Italy Abstract   PDF
Americo Cicchetti, Matteo Ruggeri, Paola Codella, Alessandro Ridolfi
 
Vol 7, No 4 (2006) The health-economic models: practical aspects and management of uncertainty Abstract   PDF
Sergio Iannazzo
 
Vol 10, No 4 (2009) The pharmaceutical expenditure in Italy in 2009: toward regional federalism Details   PDF
Mario Eandi
 
Vol 13, No 2 (2012) The public and patients should have their say in HTA Details   HTML   PDF
Leela Barham
 
Vol 16, No 4 (2015) The regulatory and Health Technology processes in Europe and drug market access. The case of cystic fibrosis Abstract   HTML   PDF
Mayra Latorre Martinez, Pedro Serrano, Antonio Sarria Santamera
 
Vol 15, No 4 (2014) The trend of pharmaceutical expenditure in Italy: from the report OsMed 2013 to the monitoring 2014 Details   HTML   PDF
Mario Eandi
 
Vol 10, No 4 (2009) The use of corticosteroids in patients with chronic obstructive pulmonary disease: epidemiological and economic aspects Abstract   PDF
Pablo M. Katz, Valeria Pegoraro
 
Vol 14, No 1S (2013) The use of dexmedetomidine in intensive care sedation Abstract   HTML   PDF
Massimo Antonelli, Giorgio Conti, Andrea Belisari, Lucia S. D'Angiolella, Lorenzo Mantovani, Sabato Montella, Patrizio Piacentini, Marco Ranieri
 
Vol 14, No 3 (2013) The utility of a model-based cost-effectiveness analysis of degarelix versus leuprolide in the therapy of hormone-dependent advanced prostate cancer Abstract   HTML   PDF
Massimo Perachino, Mario Eandi
 
Vol 10, No 2 (2009) Theory and practice of the Health Technology Assessment in countries with a predominant public health service Details   PDF
Mario Eandi
 
Vol 7, No 4 (2006) Tigecycline: a review of the literature Abstract   PDF
Mario Venditti, Maria Elena Pompeo, Flavia Fabi
 
Vol 12, No 2 (2011) Tiotropium bromide in the routine care of GOLD stage II COPD patients: a pharmaeconomic evaluation Abstract   HTML   PDF
Orietta Zaniolo, Michela Carsi, Sergio Iannazzo
 
Vol 11, No 1 (2010) Tiotropium in COPD: clinical outcomes and economic evidence Abstract   PDF
Orietta Zaniolo, Viola Sacchi, Roberto W. Dal Negro
 
Vol 13, No 2S (2012) Toscana Abstract   HTML   PDF
Roberto Gasparini, Donatella Panatto, Bruna Dirodi, Rosa Prato, Gianni Amunni, Valter Turello, Luigi Sudano, Paolo Cristoforoni, Sara Boccalini, Paolo Bonanni
 
Vol 9, No 1S (2008) Toscana Abstract   PDF
Maria Caterina Cavallo, Filippo Cipriani, Simone Gerzeli, Nadia Demarteau, Alessia Marocco, Francesco Bamfi
 
Vol 2, No 1 (2001) Traiettorie tecniche e Metodologia QWERTY: come si applicano alle innovazioni farmaceutiche Abstract   PDF
Marina Altagracia, Mario Cimoli, Jaime Kravzov, Rafael Castillo, Ofelia Espejo, Albert I. Wertheimer
 
Vol 5, No 3 (2004) Tramadolo: profilo farmacologico, terapeutico e farmacoeconomico Abstract   PDF
Loredana Serpe, Lorenzo Pradelli, Mario Eandi
 
Vol 4, No 1 (2003) Trattamento con etanercept dei soggetti con artrite reumatoide in Italia: considerazioni economiche Abstract   PDF
Lorenzo G. Mantovani
 
Vol 14, No 1 (2013) Treatment cost of metastatic colon cancer in Turkey Abstract   HTML   PDF
Guvenc Kockaya, Mine Polat, Albert Wertheimer, Ahmet Ozet, Simten Malhan, İsmail Mert Vural, Akif Akbulat, Guven Artıran, Hakkı Gursoz, Saim Kerman
 
Vol 10, No 4 (2009) Trends in prescribing and persistence with antihypertensive therapy: results of the study PAPEETE (Population-based Analysis of Persistence and Economics of treatment with telmisartan) study Abstract   PDF
Francesco Vittorio Costa
 
Vol 13, No 2S (2012) Trento Abstract   HTML   PDF
Roberto Gasparini, Donatella Panatto, Bruna Dirodi, Rosa Prato, Gianni Amunni, Valter Turello, Luigi Sudano, Paolo Cristoforoni, Sara Boccalini, Paolo Bonanni
 
Vol 9, No 1S (2008) Trento Abstract   PDF
Maria Caterina Cavallo, Filippo Cipriani, Simone Gerzeli, Nadia Demarteau, Alessia Marocco, Francesco Bamfi
 
Vol 13, No 2S (2012) Umbria Abstract   HTML   PDF
Roberto Gasparini, Donatella Panatto, Bruna Dirodi, Rosa Prato, Gianni Amunni, Valter Turello, Luigi Sudano, Paolo Cristoforoni, Sara Boccalini, Paolo Bonanni
 
Vol 9, No 1S (2008) Umbria Abstract   PDF
Maria Caterina Cavallo, Filippo Cipriani, Simone Gerzeli, Nadia Demarteau, Alessia Marocco, Francesco Bamfi
 
Vol 1, No 2 (2000) Una checklist per la gestione dei costi nel trattamento dell’HIV Abstract   PDF
Vasilisa Sazonov, Uros Urleb, Albert L. Wertheimer
 
Vol 5, No 4 (2004) Una valutazione economica di citrato di fentanile ad assorbimento orale (Actiq®) per la terapia del dolore in pazienti affetti da cancro Abstract   PDF
C. Lucioni, S. Mazzi
 
Vol 3, No 4 (2002) Unita di consumo dei farmaci e valutazioni farmacoeconomiche: uso e misuso di DDD e PDD Abstract   PDF
Mario Eandi
 
Vol 9, No 4 (2008) Usefulness and limitation of DDD and PDD analyses. 12 months of solid oral antipsychotics prescribing data for the NHS-reimbursed treatment of schizophrenia in Italy Abstract   PDF
Lorenzo Pradelli
 
Vol 16, No 3 (2015) Using Patient-Reported Outcomes to Include the Patient in Research, Care, and Quality Details   HTML   PDF
Priya Gaur, Nikita Jeswani, Nelly Ganesan
 
Vol 3, No 3 (2002) Utilità e costo/efficacia del dinoprostone in ostetricia Abstract   PDF
Mario Eandi, Lorenzo Pradelli, Chiara Benedetto
 
Vol 18, No 1 (2017) Utilization patterns of complementary and alternative medicine in Australia, Canada and the United States: popularity of dietary supplements, mind-body and manipulative therapies Details   HTML   PDF
Marina Luketina Sunjka, Ana Pejcic, Mihajlo Jakovljevic
 
Vol 13, No 2S (2012) Valle d’Aosta Abstract   HTML   PDF
Roberto Gasparini, Donatella Panatto, Bruna Dirodi, Rosa Prato, Gianni Amunni, Valter Turello, Luigi Sudano, Paolo Cristoforoni, Sara Boccalini, Paolo Bonanni
 
Vol 9, No 1S (2008) Valle d’Aosta Abstract   PDF
Maria Caterina Cavallo, Filippo Cipriani, Simone Gerzeli, Nadia Demarteau, Alessia Marocco, Francesco Bamfi
 
Vol 12, No 1S (2011) Valsartan: come versatilità e tollerabilità possono contribuireal contenimento della spesa sanitaria Abstract   PDF
Francesco Vittorio Costa
 
Vol 13, No 4 (2012) Value of drug or valuable drug: a point of view issue Details   HTML   PDF
Francesca Patarnello
 
Vol 6, No 4 (2005) Valutazione clinica e metabolica dell’impiego dell’insulina Lispro in pazienti con diabete mellito scompensato Abstract   PDF
Antonio Uneddu, Tito Antonio Paolini
 
Vol 2, No 4 (2001) Valutazione dei costi di trattamento dei disturbi psicotici con olanzapina, risperidone e neurolettici tipici di un DSM italiano Abstract   PDF
I. Rossi, L. Guidi
 
Vol 12, No 2S (2011) Valutazione dei processi assistenziali e del carico economico dei soggetti con ospedalizzazione incidente di infarto acuto del miocardio mediante il Data Warehouse DENALI Abstract   PDF
Lorenzo G. Mantovani, Carla Fornari, Fabiana Madotto, Michele A. Riva, Luca Merlino, Virginio Chiodini, Giancarlo Cesana
 
Vol 4, No 1 (2003) Valutazione del turn over dei farmaci antiretrovirali in particolare da IP a NNRTI Abstract   PDF
Sergio Sabbatani, Raffaella Cesari, Emanuela Pipitone, Francesco Chiodo
 
Vol 2, No 2 (2001) Valutazione dell’impatto delle politiche del prezzo di riferimento sul mercato degli H2-antagonisti nella British Columbia, Canada Abstract   PDF
Lutchmie Narine, Mahil Senathirajah, Tina Smith, Albert I. Wertheimer
 
Vol 14, No 1 (2013) Valutazione di efficienza nella somministrazione dell’ormone della crescita (GH) Abstract   HTML   PDF
Federico Spandonaro, Letizia Mancusi
 
Vol 6, No 4 (2005) Valutazione economica dei costi associati al trattamento di pazienti in ossigenoterapia a lungo termine, con o senza monitoraggio telemetrico domiciliare Abstract   PDF
Roberto Ravasio, Roberto W. Dal Negro, Carlo Lucioni
 
Vol 8, No 2S (2007) Valutazione economica delle terapie farmacologiche Details   PDF
Lorenzo G. Mantovani, Simona Cammarota
 
Vol 8, No 2S (2007) Valutazione economica dello studio AVERT Abstract   PDF
Simona De Portu, Simona Cammarota, Enrica Menditto, Lorenzo G. Mantovani
 
Vol 8, No 2S (2007) Valutazione economica dello studio CARDS Abstract   PDF
Simona de Portu, Enrica Menditto, Lorenzo G. Mantovani
 
Vol 12, No 2S (2011) Valutazione economica dello studio CARDS: un aggiornamento Abstract   PDF
Simona de Portu, Sabato Montella, Paolo Cortesi, Enrica Menditto, Lorenzo G. Mantovani
 
Vol 8, No 2S (2007) Valutazione economica dello studio IDEAL Abstract   PDF
Enrica Menditto, Anna Citarella
 
Vol 8, No 2S (2007) Valutazione economica dello studio MIRACL Abstract   PDF
Simona De Portu, Sabato Montella, Simona Cammarota, Lorenzo G. Mantovani
 
301 - 400 of 432 Items << < 1 2 3 4 5 > >>